Industry Focus

The much-maligned company is making progress on its restructuring plan, but it's not out of the woods yet. Plus, why Keryx Pharmaceuticals shares tumbled despite winning an FDA approval that more than doubles its addressable market.

Direct download: 20171108_IF_HEalthcare.mp3
Category:Podcast -- posted at: 3:53pm EST